Publications

  1. Tefferi A, Partain DK, Palmer JM, Slack JL, Roy V, Hogan WJ, Litzow ML, Ketterling RP, Patnaik MM. Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. Am J Hematol. 2018 May; 93 (5):649-654 Epub 2018 Feb 24
    View PubMed
  2. Gangat N, Mudireddy M, Lasho TL, Finke CM, Nicolosi M, Szuber N, Patnaik MM, Pardanani A, Hanson CA, Ketterling RP, Tefferi A. Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. Am J Hematol. 2018 May; 93 (5):691-697 Epub 2018 Feb 24
    View PubMed
  3. Hoversten K, Vallapureddy R, Lasho T, Finke C, Ketterling R, Hanson C, Gangat N, Tefferi A, Patnaik MM. Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. Leuk Lymphoma. 2018 Mar 27; 1-4 [Epub ahead of print]
    View PubMed
  4. Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Szuber N, Begna KH, Patnaik MM, Gangat N, Pardanani A, Tefferi A. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. Blood Adv. 2018 Feb 27; 2 (4):370-380
    View PubMed
  5. Al-Kali A, Abou Hussein AK, Patnaik M, Zblewski D, Gangat N, Hashmi S, Elliott M, Hogan W, Litzow M. Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. Leuk Lymphoma. 2018 Feb 21; 1-3 [Epub ahead of print]
    View PubMed
  6. Tefferi A, Mudireddy M, Mannelli F, Begna KH, Patnaik MM, Hanson CA, Ketterling RP, Gangat N, Yogarajah M, De Stefano V, Passamonti F, Rosti V, Finazzi MC, Rambaldi A, Bosi A, Guglielmelli P, Pardanani A, Vannucchi AM. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia. 2018 Feb 2 Epub 2018 Feb 02
    View PubMed
  7. Patnaik MM, Ketterling RP, Tefferi A. FGFR1 rearranged hematological neoplasms - molecularly defined and clinically heterogeneous. Leuk Lymphoma. 2018 Jan 31; 1-3 [Epub ahead of print]
    View PubMed
  8. Kazamel M, Klein CJ, Benarroch EE, Patnaik MM, Tracy JA. Subacute demyelinating polyradiculoneuropathy complicating Epstein-Barr virus infection in GATA2 haploinsufficiency. Muscle Nerve. 2018 Jan; 57 (1):150-156 Epub 2017 Mar 18
    View PubMed
  9. Patnaik MM, Vallapureddy R, Yalniz FF, Hanson CA, Ketterling RP, Lasho TL, Finke C, Al-Kali A, Gangat N, Tefferi A. Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. Am J Hematol. 2018 Jan; 93 (1):65-73 Epub 2017 Nov 03
    View PubMed
  10. Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, Rybka W, Artz A, Porter DL, Shea TC, Boyer MW, Maziarz RT, Shaughnessy PJ, Gergis U, Safah H, Reshef R, DiPersio JF, Stiff PJ, Vusirikala M, Szer J, Holter J, Levine JD, Martin PJ, Pidala JA, Lewis ID, Ho VT, Alyea EP, Ritz J, Glavin F, Westervelt P, Jagasia MH, Chen YB. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. J Clin Oncol. 2017 Dec 20; 35 (36):4003-4011 Epub 2017 Oct 17
    View PubMed
  11. Tefferi A, Lasho TL, Patnaik MM, Saeed L, Mudireddy M, Idossa D, Finke C, Ketterling RP, Pardanani A, Gangat N. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R. Am J Hematol. 2017 Dec; 92 (12):1311-1317 Epub 2017 Oct 20
    View PubMed
  12. Lehman JS, Hashmi SK, Lazarus HM, El-Azhary RA, Gibson LE, Hogan WJ, Litzow MR, Patnaik MS, Buadi F, Lacy MQ, Dasari S, Vanderboom P, Meves A. Immunophenotypic and molecular comparison between allogeneic and autologous graft-vs-host disease of the skin: A retrospective study using immunohistochemical and proteomics methods. J Cutan Pathol. 2017 Dec; 44 (12):1087-1091 Epub 2017 Sept 14
    View PubMed
  13. Marshall AL, Perez Botero J, Botero JP, Ashrani AA, Pruthi RK, Heit JA, Chintakuntlawar A, Guenther JC, Patnaik MM. The Impact of Antithrombin Deficiency on Women's Reproductive Health Experiences and Healthcare Decision-Making. J Womens Health (Larchmt). 2017 Dec; 26 (12):1350-1355 Epub 2017 Sept 21
    View PubMed
  14. Damlaj M, Patnaik MM. Toward Individualizing Conditioning Regimens in Reduced-Intensity Transplantation. Biol Blood Marrow Transplant. 2017 Dec; 23 (12):2019-2020 Epub 2017 Oct 12
    View PubMed
  15. Patnaik MM. The importance of FLT3 mutational analysis in acute myeloid leukemia. Leuk Lymphoma. 2017 Nov 22; 1-14 [Epub ahead of print]
    View PubMed
  16. Sterner RM, Kremer KN, Al-Kali A, Patnaik MM, Gangat N, Litzow MR, Kaufmann SH, Westendorf JJ, van Wijnen AJ, Hedin KE. Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine. Oncotarget. 2017 Nov 7; 8 (55):94569-94579 Epub 2017 Oct 10
    View PubMed
  17. Barreto JN, McCullough KB, Peskey CS, Dierkhising RA, Mara KC, Elliott MA, Gastineau DA, Al-Kali A, Gangat N, Letendre L, Hogan WJ, Litzow MR, Patnaik MM. Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy(). Leuk Lymphoma. 2017 Nov; 58 (11):2588-2597 Epub 2017 May 09
    View PubMed
  18. Hefazi M, Patnaik MM, Hogan WJ, Litzow MR, Pardi DS, Khanna S. Safety and Efficacy of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. Mayo Clin Proc. 2017 Nov; 92 (11):1617-1624 Epub 2017 Nov 01
    View PubMed
  19. Webster JA, Tibes R, Morris L, Blackford AL, Litzow M, Patnaik M, Rosner GL, Gojo I, Kinders R, Wang L, Doyle LA, Huntoon CJ, Karnitz LM, Kaufmann SH, Karp JE, Smith BD. Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. Leuk Res. 2017 Oct; 61:108-116 Epub 2017 Sept 20
    View PubMed
  20. Nanah R, McCullough K, Hogan W, Begna K, Patnaik M, Elliott M, Litzow M, Al-Kali A. Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience. Am J Hematol. 2017 Sep; 92 (9):866-871 Epub 2017 June 05
    View PubMed
  21. Yalniz FF, Hefazi M, McCullough K, Litzow MR, Hogan WJ, Wolf R, Alkhateeb H, Kansagra A, Damlaj M, Patnaik MM. Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Sep; 23 (9):1478-1484 Epub 2017 May 08
    View PubMed
  22. Patnaik MM. Midostaurin for the treatment of acute myeloid leukemia. Future Oncol. 2017 Sep; 13 (21):1853-1871 Epub 2017 June 14
    View PubMed
  23. Moyer AM, Hashmi SK, Kroning CM, Kremers WK, De Goey SR, Patnaik M, Litzow M, Gastineau DA, Hogan WJ, Jacob EK, Kreuter JD, Wakefield LL, Gandhi MJ. Clinical outcomes of HLA-DPB1 mismatches in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant. Eur J Haematol. 2017 Sep; 99 (3):275-282 Epub 2017 July 21
    View PubMed
  24. Goyal G, Bartley AC, Patnaik MM, Litzow MR, Al-Kali A, Go RS. Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set. Blood Cancer J 2017 Aug 25; 7 (8):e592
    View PubMed
  25. Perez Botero J, Chen D, Cousin MA, Majerus JA, Coon LM, Kruisselbrink TM, Klee EW, Lazaridis KN, Pruthi RK, Patnaik MM. Clinical characteristics and platelet phenotype in a family with RUNX1 mutated thrombocytopenia. Leuk Lymphoma 2017 Aug; 58 (8):1963-1967 Epub 2016 Dec 08
    View PubMed
  26. Mangaonkar AA, Patnaik MM. Patterns of Care and Survival for Elderly Acute Myeloid Leukemia-Challenges and Opportunities. Curr Hematol Malig Rep. 2017 Aug; 12 (4):290-299
    View PubMed
  27. Patnaik MM, Timm MM, Vallapureddy R, Lasho TL, Ketterling RP, Gangat N, Shi M, Tefferi A, Solary E, Reichard KK, Jevremovic D. Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. Blood Cancer J 2017 Jul 21; 7 (7):e584 Epub 2017 July 21
    View PubMed
  28. Gupta A, Viswanatha DS, Patnaik MM. FLT3 Mutation Testing in Acute Myeloid Leukemia. JAMA Oncol. 2017 Jul 1; 3 (7):991-992
    View PubMed
  29. Barraco D, Cerquozzi S, Gangat N, Patnaik MM, Lasho T, Finke C, Hanson CA, Ketterling RP, Pardanani A, Tefferi A. Monocytosis in polycythemia vera: Clinical and molecular correlates. Am J Hematol. 2017 Jul; 92: (7)640-645.
    View PubMed
  30. Dorn JM, Patnaik MS, Van Hee M, Smith MJ, Lagerstedt SA, Newman CC, Boyce TG, Abraham RS. WILD syndrome is GATA2 deficiency: A novel deletion in the GATA2 gene. J Allergy Clin Immunol Pract. 2017 Jul - Aug; 5: (4)1149-1152.e1.
    View PubMed
  31. Gurney M, Patnaik MM, Hanson CA, Litzow MR, Al-Kali A, Ketterling RP, Tefferi A, Gangat N. The 2016 revised World Health Organization definition of 'myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single versus double cytogenetic abnormalities. Br J Haematol. 2017 Jul; 178 (1):57-60 Epub 2017 Apr 17
    View PubMed
  32. Perez Botero J, Pruthi RK, Majerus JA, Coon LM, Uhl CB, Chen D, Patnaik MM. Practice patterns in the diagnosis of inherited platelet disorders within a single institution. Blood Coagul Fibrinolysis. 2017 Jun; 28 (4):303-308
    View PubMed
  33. Zahid MF, Barraco D, Lasho TL, Finke C, Ketterling RP, Gangat N, Hanson CA, Tefferi A, Patnaik MM. Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. Leuk Lymphoma 2017 Jun; 58 (6):1488-1493 Epub 2016 Oct 14
    View PubMed
  34. Patnaik MM, Barraco D, Lasho TL, Finke CM, Reichard K, Hoversten KP, Ketterling RP, Gangat N, Tefferi A. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol. 2017 Jun; 92 (6):542-548 Epub 2017 Apr 29
    View PubMed
  35. Perez Botero J, Ho TP, Hogan WJ, Kenderian S, Gangat N, Tefferi A, Abraham RS, Nguyen P, Oliveira JL, He R, Chen D, Viswanatha D, Rodriguez V, Khan SP, Patnaik MM. Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. Br J Haematol 2017 May 09 [Epub ahead of print]
    View PubMed
  36. Farhadfar N, Cerquozzi S, Hessenauer MR, Litzow MR, Hogan WJ, Letendre L, Patnaik MM, Tefferi A, Gangat N. Acute leukemia in pregnancy: a single institution experience with 23 patients. Leuk Lymphoma. 2017 May; 58 (5):1052-1060 Epub 2016 Aug 26
    View PubMed
  37. Bryce AH, Egan JB, Borad MJ, Stewart AK, Nowakowski GS, Chanan-Khan A, Patnaik MM, Ansell SM, Banck MS, Robinson SI, Mansfield AS, Klee EW, Oliver GR, McCormick JB, Huneke NE, Tagtow CM, Jenkins RB, Rumilla KM, Kerr SE, Kocher JA, Beck SA, Fernandez-Zapico ME, Farrugia G, Lazaridis KN, McWilliams RR. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. Oncotarget. 2017 Apr 18; 8 (16):27145-27154
    View PubMed
  38. Sharma P, Shinde SS, Damlaj M, Hefazi Rorghabeh M, Hashmi SK, Litzow MR, Hogan WJ, Gangat N, Elliott MA, Al-Kali A, Tefferi A, Patnaik MM. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. Leuk Lymphoma. 2017 Apr; 58 (4):872-881 Epub 2016 Aug 11
    View PubMed
  39. Saeed L, Patnaik MM, Begna KH, Al-Kali A, Litzow MR, Hanson CA, Ketterling RP, Porrata LF, Pardanani A, Gangat N, Tefferi A. Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. Blood Cancer J. 2017 Mar 31; 7 (3):e550
    View PubMed
  40. Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017 Mar; 92 (3):297-310
    View PubMed
  41. Shenoy N, Stenson M, Lawson J, Abeykoon J, Patnaik M, Wu X, Witzig T. Drugs with anti-oxidant properties can interfere with cell viability measurements by assays that rely on the reducing property of viable cells. Lab Invest. 2017 Feb 27;
    View PubMed
  42. Durani U, Dioverti Prono MV, Tosh PK, Patnaik M, Barreto JN, Tande AJ. Influenza infection in neutropenic adults. Infect Dis (Lond). 2017 Feb; 49 (2):141-146 Epub 2016 Sept 16
    View PubMed
  43. Patnaik MM, Barraco D, Lasho TL, Finke CM, Hanson CA, Ketterling RP, Gangat N, Tefferi A. DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. Am J Hematol. 2017 Jan; 92 (1):56-61 Epub 2016 Dec 07
    View PubMed
  44. Mangaonkar A, Khateeb HA, Duma N, Louis EKS, McKeon A, Patnaik M, Hogan W, Litzow M, Kourelis T. Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia. Case Rep Hematol. 2017; 2017:6803804 Epub 2017 Aug 27
    View PubMed
  45. Hefazi M, Damlaj M, Alkhateeb HB, Partain DK, Patel R, Razonable RR, Gastineau DA, Al-Kali A, Hashmi SK, Hogan WJ, Litzow MR, Patnaik MM. Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. Transpl Infect Dis. 2016 Dec; 18 (6):913-920 Epub 2016 Nov 11
    View PubMed
  46. Perez Botero J, Chen D, He R, Viswanatha DS, Majerus JA, Coon LM, Nguyen PL, Reichard KK, Oliveira JL, Tefferi A, Gangat N, Pruthi RK, Patnaik MM. Clinical and laboratory characteristics in congenital ANKRD26 mutation-associated thrombocytopenia: A detailed phenotypic study of a family. Platelets. 2016 Nov; 27 (7):712-715 Epub 2016 Apr 28
    View PubMed
  47. Patnaik MM, Lasho TL, Finke CM, Hanson CA, King RL, Ketterling RP, Gangat N, Tefferi A. Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis. Leukemia 2016 Nov; 30 (11):2273-2275 Epub 2016 Aug 01
    View PubMed
  48. Nanah R, Zblewski D, Patnaik MS, Begna K, Ketterling R, Iyer VN, Hogan WJ, Litzow MR, Al-Kali A. Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. Leuk Res. 2016 Nov; 50:112-115 Epub 2016 Oct 03
    View PubMed
  49. Lichtenstein DA, Crispin AW, Sendamarai AK, Campagna DR, Schmitz-Abe K, Sousa CM, Kafina MD, Schmidt PJ, Niemeyer CM, Porter J, May A, Patnaik MM, Heeney MM, Kimmelman A, Bottomley SS, Paw BH, Markianos K, Fleming MD. A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia. Blood. 2016 Oct 13; 128 (15):1913-1917 Epub 2016 Aug 03
    View PubMed
  50. Zahid MF, Patnaik MM, Gangat N, Hashmi SK, Rizzieri DA. Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy. Eur J Haematol. 2016 Oct; 97 (4):313-20 Epub 2016 May 31
    View PubMed
  51. Patnaik MM, Zahid MF, Lasho TL, Finke C, Ketterling RL, Gangat N, Robertson KD, Hanson CA, Tefferi A. Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance. Blood Cancer J. 2016 Sep 23; 6: (9)e472.
    View PubMed
  52. Zahid MF, Murad MH, Litzow MR, Hogan WJ, Patnaik MS, Khorana A, Spyropoulos AC, Hashmi SK. Venous thromboembolism following hematopoietic stem cell transplantation-a systematic review and meta-analysis. Ann Hematol. 2016 Sep; 95: (9)1457-64.
    View PubMed
  53. Narayanan P, Wolanskyj A, Ehlers SL, Litzow MR, Patnaik MS, Hogan WJ, Hashmi SK. Medical Students' Knowledge, Familiarity, and Attitudes towards Hematopoietic Stem Cell Donation: Stem Cell Donation Behaviors. Biol Blood Marrow Transplant. 2016 Sep; 22 (9):1710-1716 Epub 2016 June 22
    View PubMed
  54. Ravandi F, Gojo I, Patnaik MM, Minden MD, Kantarjian H, Johnson-Levonas AO, Fancourt C, Lam R, Jones MB, Knox CD, Rose S, Patel PS, Tibes R. A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). Leuk Res. 2016 Sep; 48:92-100 Epub 2016 July 25
    View PubMed
  55. Narayanan P, Wolanskyj A, Ehlers SL, Litzow MR, Patnaik MS, Hogan WJ, Hashmi SK. Medical students' knowledge, familiarity, and attitudes towards hematopoietic stem cell donation stem cell donation behaviors Biology Of Blood And Marrow Transplantation. 2016 Sep; 22: (9)1710-6.
  56. Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: molecularly contaminated, but not defined. Leuk Lymphoma 2016 Aug; 57 (8):1751-2 Epub 2016 Apr 11
    View PubMed
  57. Damlaj M, Alkhateeb HB, Hefazi M, Partain DK, Hashmi S, Gastineau DA, Al-Kali A, Wolf RC, Gangat N, Litzow MR, Hogan WJ, Patnaik MM. Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. Biol Blood Marrow Transplant. 2016 Aug; 22 (8):1431-1439 Epub 2016 May 07
    View PubMed
  58. Subari S, Patnaik M, Alfakara D, Zblewski D, Hook C, Hashmi S, Hogan W, Litzow M, Al-Kali A. Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia. Leuk Lymphoma 2016 Jul; 57 (7):1714-5 Epub 2016 Mar 14
    View PubMed
  59. He R, Wiktor AE, Durnick DK, Kurtin PJ, Van Dyke DL, Tefferi A, Patnaik MS, Ketterling RP, Hanson CA. Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization: Defining an Effective Utilization Strategy for Evaluation of Myelodysplastic Syndromes. Am J Clin Pathol. 2016 Jul; 146 (1):86-94 Epub 2016 June 27
    View PubMed
  60. Farhadfar N, Cerquozzi S, Patnaik M, Tefferi A. Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review. J Oncol Pract. 2016 Jul; 12 (7):611-21
    View PubMed
  61. Perez Botero J, Im R, Chen D, Patnaik MM. Grey platelet syndrome misdiagnosed as ITP. Br J Haematol. 2016 Jun; 173 (5):662 Epub 2016 May 12
    View PubMed
  62. Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management. Am J Hematol. 2016 Jun; 91: (6)631-42.
    View PubMed
  63. Perez Botero J, Patnaik MM. Fanconi Anemia-Protean Manifestations of Defective DNA Repair. Mayo Clin Proc. 2016 Jun; 91 (6):824-5
    View PubMed
  64. Patnaik MM, Lasho TL, Finke CM, Hanson CA, King RL, Ketterling RP, Gangat N, Tefferi A. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. Am J Hematol. 2016 May; 91: (5)492-8.
    View PubMed
  65. Perez Botero J, Ormsby WD, Ashrani AA, McBane RD 2nd, Wysokinski WE, Patnaik MM, Lewis BR, Grill DE, Pruthi RK, Heit JA. Do incident and recurrent venous thromboembolism risks truly differ between heterozygous and homozygous Factor V Leiden carriers? A retrospective cohort study. Eur J Intern Med. 2016 May; 30:77-81.
    View PubMed
  66. Gangat N, Patnaik MM, Begna K, Al-Kali A, Litzow MR, Ketterling RP, Hanson CA, Pardanani AD, Tefferi A. Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment. Blood Cancer J. 2016 Apr 08; 6:e414.
    View PubMed
  67. Chaudhry HM, Bruce AJ, Wolf RC, Litzow MR, Hogan WJ, Patnaik MS, Kremers WK, Phillips GL, Hashmi SK. The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. Biol Blood Marrow Transplant. 2016 Apr; 22 (4):605-616 Epub 2015 Sept 26
    View PubMed
  68. Subari S, Baidoun F, Hreh M, Patnaik M, Hashmi S, Elliott M, Hogan W, Litzow M, Al-Kali A. Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy. Int J Hematol. 2016 Apr; 103 (4):409-15 Epub 2016 Jan 18
    View PubMed
  69. Damlaj M, Bartoo G, Cartin-Ceba R, Gijima D, Alkhateeb HB, Merten J, Hashmi S, Litzow M, Gastineau D, Hogan W, Patnaik MM. Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients. Transpl Infect Dis. 2016 Apr; 18: (2)216-26.
    View PubMed
  70. Shen W, Patnaik MM, Ruiz A, Russell SJ, Peng KW. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood. 2016 Mar 17; 127 (11):1449-58 Epub 2015 Dec 28
    View PubMed
  71. Tefferi A, Al-Kali A, Begna KH, Patnaik MM, Lasho TL, Rizo A, Wan Y, Hanson CA. Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. Blood Cancer J. 2016 Mar 11; 6:e405.
    View PubMed
  72. Barajas MR, McCullough KB, Merten JA, Dierkhising RA, Bartoo GT, Hashmi SK, Hogan WJ, Litzow MR, Patnaik MM, Wilson JW, Wolf RC, Wermers RA. Correlation of Pain and Fluoride Concentration in Allogeneic Hematopoietic Stem Cell Transplant Recipients on Voriconazole. Biol Blood Marrow Transplant. 2016 Mar; 22: (3)579-83.
    View PubMed
  73. Patnaik MM, Tefferi A. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J. 2016 Feb 05; 6:e393.
    View PubMed
  74. Hefazi M, Litzow M, Hogan W, Gastineau D, Jacob E, Damlaj M, Hashmi S, Al-Kali A, Patnaik MM. ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning. Transfusion. 2016 Feb; 56: (2)518-27.
    View PubMed
  75. Reneau JC, Patnaik MM. 47-Year-Old Man With Pruritus. Mayo Clin Proc. 2016 Feb; 91: (2)241-5.
    View PubMed
  76. Patnaik MM, Tefferi A. Chronic Myelomonocytic Leukemia: Focus on Clinical Practice. Mayo Clin Proc. 2016 Feb; 91: (2)259-72.
    View PubMed
  77. Patnaik MM, Lasho TL, Vijayvargiya P, Finke CM, Hanson CA, Ketterling RP, Gangat N, Tefferi A. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J. 2016 Jan 15; 6:e385.
    View PubMed
  78. Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: Contemporary review and how we treat. Am J Hematol. 2016 Jan; 91: (1)76-89.
    View PubMed
  79. Pophali PA, Patnaik MM. The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Cancer J. 2016 Jan-Feb; 22: (1)40-50.
    View PubMed
  80. Kasi PM, Litzow MR, Patnaik MM, Hashmi SK, Gangat N. Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets. Leuk Res Rep. 2016; 5:7-10.
    View PubMed
  81. Yun S, Vincelette ND, Abraham I, Robertson KD, Fernandez-Zapico ME, Patnaik MM. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials. Clin Epigenetics. 2016; 8:68.
    View PubMed
  82. Gangat N, Patnaik MM, Begna K, Kourelis T, Al-Kali A, Elliott MA, Hogan WJ, Letendre L, Litzow MR, Knudson RA, Ketterling RP, Hodnefield JM, Hanson CA, Pardanani AD, Tefferi A. Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. Mayo Clin Proc. 2015 Dec; 90: (12)1623-38.
    View PubMed
  83. Damlaj M, Sulai NH, Oliveira JL, Ketterling RP, Hashmi S, Witzig T, Nowakowski G, Call TG, Shanafelt TD, Ding W, Hogan WJ, Litzow MR, Patnaik MM. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15 (11):699-704 Epub 2015 Aug 05
    View PubMed
  84. Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM, Laborde RR, Wassie E, Schimek L, Hanson CA, Gangat N, Wang X, Pardanani A. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. N Engl J Med. 2015 Sep 3; 373(10):908-19.
    View PubMed
  85. Hefazi M, Siddiqui M, Patnaik M, Wolanskyj A, Alkhateeb H, Zblewski D, Elliott M, Hogan W, Litzow M, Al-Kali A. Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. Leuk Res. 2015 Sep 3. [Epub ahead of print]
    View PubMed
  86. McCullough KB, Patnaik MM. Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update. Curr Hematol Malig Rep. 2015 Sep; 10 (3):292-302
    View PubMed
  87. Subari S, Patnaik M, Alfakara D, Gangat N, Elliott M, Hogan W, Litzow M, Al-Kali A. Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience. Clin Lymphoma Myeloma Leuk. 2015 Sep; 15: (9)546-9.
    View PubMed
  88. Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Colla S, Fenaux P, Kantarjian HM, Killick S, Sekeres MA, List AF, Onida F, Komrokji RS, Tefferi A, Solary E. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015 Jul 31; 5:e333.
    View PubMed
  89. Gupta A, Patnaik MM, Naina HV. Angiosarcoma of the Prostate Gland following Brachytherapy for Prostatic Adenocarcinoma. Curr Urol. 2015 Jul; 8: (2)109-12.
    View PubMed
  90. Pardanani A, Lasho T, Chen D, Kimlinger TK, Finke C, Zblewski D, Patnaik MM, Reichard KK, Rowinsky E, Hanson CA, Brooks C, Tefferi A. Aberrant expression of CD123 (interleukin-3 receptor-alpha) on neoplastic mast cells. Leukemia 2015 Jul; 29 (7):1605-8 Epub 2015 Feb 02
    View PubMed
  91. Barreto JN, Kuth JC, Peskey CS, Dierkhising RA, Gangat N, Patnaik MS. Acute Promyelocytic Leukemia patients receiving ATRA with and without voriconazole prophylaxis: effect on incidence and outcomes of differentiation syndrome British Journal of Medicine and Medical Research.2015;9:(4):1-8.
  92. Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts and RARS with thrombocytosis. Am J Hematol. 2015 Jun; 90: (6)549-59.
    View PubMed
  93. Perez Botero J, Oliveira JL, Chen D, Reichard KK, Viswanatha DS, Nguyen PL, Pruthi RK, Majerus J, Gada P, Gangat N, Tefferi A, Patnaik MM. ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26. Blood Cancer J 2015 May 22; 5:e315
    View PubMed
  94. Patnaik MM, Wassie EA, Lasho TL, Hanson CA, Ketterling R, Tefferi A. Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. Am J Hematol. 2015 May; 90(5):411-6. Epub 2015 Apr 01.
    View PubMed
  95. Mir MA, Kochuparambil ST, Abraham RS, Rodriguez V, Howard M, Hsu AP, Jackson AE, Holland SM, Patnaik MM. Spectrum of myeloid neoplasms and immune deficiency associated with germline GATA2 mutations. Cancer Med. 2015 Apr; 4(4):490-9. Epub 2015 Jan 26.
    View PubMed
  96. Wojenski DJ, Bartoo GT, Merten JA, Dierkhising RA, Barajas MR, El-Azhary RA, Wilson JW, Plevak MF, Hogan WJ, Litzow MR, Patnaik MM, Wolf RC, Hashmi SK. Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients. Transpl Infect Dis. 2015 Apr; 17: (2)250-8.
    View PubMed
  97. Alsahlawi A, Alkhateeb H, Patnaik M, Begna K, Elliott M, Hogan WJ, Litzow M, Al-Kali A. Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2015 Feb; 15(2):e39-41. Epub 2014 Jun 10.
    View PubMed
  98. Lasho TL, Finke CM, Zblewski D, Patnaik M, Ketterling RP, Chen D, Hanson CA, Tefferi A, Pardanani A. Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. Blood Cancer J. 2015 Jan 23; 5:e275.
    View PubMed
  99. Patnaik MM, Wassie EA, Padron E, Onida F, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, Ketterling RP, Komrokji R, Tefferi A, Solary E. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer J. 2015 Jan 02; 5:e270.
    View PubMed
  100. Perez Botero J, Spoon DB, Patnaik MS, Ashrani AA, Trousdale RT, Pruthi RK. Incidence of symptomatic venous thromboembolism in patients with hemophilia undergoing joint replacement surgery: a retrospective study. Thromb Res. 2015 Jan; 135(1):109-13. Epub 2014 Nov 18.
    View PubMed
  101. Wassie EA, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, Ketterling RP, Solary E, Tefferi A, Patnaik MM. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. Am J Hematol. 2014 Dec; 89: (12)1111-5.
    View PubMed
  102. Patnaik MM, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, Knudson RA, Ketterling RP, Tefferi A, Solary E. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014 Nov; 28: (11)2206-12.
    View PubMed
  103. Malik MI, Litzow M, Hogan W, Patnaik M, Murad MH, Prokop LJ, Winters JL, Hashmi S. Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. Blood Res. 2014 Jun; 49: (2)100-6.
    View PubMed
  104. Patnaik MM, Parikh SA, Hanson CA, Tefferi A. Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol. 2014 May; 165(3):273-86. Epub 2014 Jan 28.
    View PubMed
  105. Thoma MD, Glejf J, Jacob E, Huneke TJ, DeCook LJ, Johnson ND, Patnaik MM, Litzow MR, Hogan WJ, Newell LF, Chandran R, Porrata LF, Holtan SG. Impact of clinical factors and allograft leukocyte content on post-transplant lymphopenia, monocytopenia, and survival in patients undergoing allogeneic peripheral blood haematopoietic cell transplant. BMC Hematol. 2014; 14: (1)14.
    View PubMed
  106. Gupta A, Patnaik MM, Naina HV. MYST3CREBBP Rearranged Acute Myeloid Leukemia after Adjuvant Chemotherapy for Breast Cancer. Case Rep Oncol Med. 2014; 2014:361748.
    View PubMed
  107. Dispenzieri A, Seenithamby K, Lacy MQ, Kumar SK, Buadi FK, Hayman SR, Dingli D, Litzow MR, Gastineau DA, Inwards DJ, Micallef IN, Ansell SM, Johnston PB, Porrata LF, Patnaik MM, Hogan WJ, Gertz MA. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. Bone Marrow Transplant. 2013 Oct; 48(10):1302-7. Epub 2013 Apr 22.
    View PubMed
  108. Gangat N, Patnaik MM, Begna K, Kourelis T, Knudson RA, Ketterling RP, Hodnefield JM, Hanson CA, Pardanani A, Tefferi A. Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. Am J Hematol. 2013 Aug; 88(8):690-3. Epub 2013 Jun 20.
    View PubMed
  109. Kourelis TV, Chen D, White JG, Gangat N, Uhl CB, Patnaik MM. Myeloid malignancy presenting with a platelet storage pool disorder. Leuk Lymphoma 2013 Aug; 54 (8):1800-1 Epub 2012 Dec 22
    View PubMed
  110. Kenderian SS, Al-Kali A, Gangat N, Letendre L, Hogan WJ, Litzow MR, Patnaik MM. Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood Cancer J. 2013 Jul 05; 3:e122.
    View PubMed
  111. Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling RP, Al-kali A, Pardanani A, Ali NA, Komrokji RS, Tefferi A. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013 Jul; 27: (7)1504-10.
    View PubMed
  112. Gonsalves WI, Zent CS, Pulido JS, Patnaik MM. Visual loss in early-stage chronic lymphocytic leukemia. J Clin Oncol. 2013 Jun 10; 31(17):e280-2. Epub 2013 May 06.
    View PubMed
  113. Lim MY, Al-Kali A, Ashrani AA, Begna KH, Elliott MA, Hogan WJ, Hook CC, Kaufmann SH, Letendre L, Litzow MR, Patnaik MS, Pardanani A, Tefferi A, Wolanskyj AP, Grill DE, Pruthi RK. Comparison of complication rates of Hickman((R)) catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapy. Leuk Lymphoma. 2013 Jun; 54(6):1263-7. Epub 2012 Nov 19.
    View PubMed
  114. DeCook LJ, Thoma M, Huneke T, Johnson ND, Wiegand RA, Patnaik MM, Litzow MR, Hogan WJ, Porrata LF, Holtan SG. Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning. Bone Marrow Transplant. 2013 May; 48(5):708-14. Epub 2012 Oct 29.
    View PubMed
  115. Gonsalves WI, Pruthi RK, Patnaik MM. The new oral anticoagulants in clinical practice. Mayo Clin Proc. 2013 May; 88(5):495-511.
    View PubMed
  116. Patnaik MM, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling RP, Pardanani A, Tefferi A. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol. 2013 Mar; 88: (3)201-6.
    View PubMed
  117. Kasi PM, Patnaik MM, Peethambaram PP. Safety of pegfilgrastim (neulasta) in patients with sickle cell traitanemia. Case Rep Hematol. 2013; 2013:146938.
    View PubMed
  118. Badiye A, Patnaik M, Deshpande A, Rajendran C, Chandrashekara KV. Think fungus NOT just a crypto-meningitis in AIDS! J Assoc Physicians India. 2012 Dec; 60:21-4.
    View PubMed
  119. Lasho TL, Jimma T, Finke CM, Patnaik M, Hanson CA, Ketterling RP, Pardanani A, Tefferi A. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood. 2012 Nov 15; 120: (20)4168-71.
    View PubMed
  120. Smeltzer JP, Viswanatha DS, Habermann TM, Patnaik MM. Secondary Epstein-Barr virus associated lymphoproliferative disorder developing in a patient with angioimmunoblastic T cell lymphoma on vorinostat. Am J Hematol. 2012 Sep; 87(9):927-8. Epub 2012 Jun 20.
    View PubMed
  121. Patnaik MM, Hanson CA, Sulai NH, Hodnefield JM, Knudson RA, Ketterling RP, Lasho TL, Tefferi A. Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. Blood. 2012 Jun 14; 119(24):5674-7. Epub 2012 Apr 26.
    View PubMed
  122. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, Steensma DP, Pardanani A, Hanson CA, Tefferi A. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012 Jan 12; 119 (2):569-72 Epub 2011 Nov 17
    View PubMed
  123. Patnaik MM, Hanson CA, Hodnefield JM, Lasho TL, Finke CM, Knudson RA, Ketterling RP, Pardanani A, Tefferi A. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia. 2012 Jan; 26(1):101-5. Epub 2011 Oct 28.
    View PubMed
  124. Stanich PP, Owens VL, Sweetser S, Khambatta S, Smyrk TC, Richardson RL, Goetz MP, Patnaik MM. Colonic polyposis and neoplasia in Cowden syndrome. Mayo Clin Proc. 2011 Jun; 86: (6)489-92.
    View PubMed
  125. Patnaik MM, Lasho TL, Finke CM, Knudson RA, Ketterling RP, Chen D, Hoyer JD, Hanson CA, Tefferi A. Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients. Am J Hematol. 2011 May; 86(5):393-8.
    View PubMed
  126. Raza S, TaherNazerHussain F, Patnaik M, Knudson R, Van Dyke, Tefferi A. Autosomal monosomies among 24,262 consecutive cytogenetic studies: prevalence, chromosomal distribution and clinicopathologic correlates of sole abnormalities. Am J Hematol. 2011 Apr; 86(4):353-6.
    View PubMed
  127. Patnaik MM, Hanson CA, Hodnefield JM, Knudson R, Van Dyke DL, Tefferi A. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia. 2011 Feb; 25(2):266-70. Epub 2010 Nov 12.
    View PubMed
  128. Saini KS, Patnaik MM, Tefferi A. Polycythemia vera-associated pruritus and its management. Eur J Clin Invest. 2010 Sep; 40(9):828-34. Epub 2010 Jul 01.
    View PubMed
  129. Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Holtan SG, Pardanani A, Knudson RA, Ketterling RP, Chen D, Hoyer JD, Hanson CA, Tefferi A. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia. 2010 Jul; 24(7):1283-9. Epub 2010 May 20.
    View PubMed
  130. Patnaik MM, Knudson RA, Gangat N, Hanson CA, Pardanani A, Tefferi A, Ketterling RP. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates. Eur J Haematol. 2010 Jun; 84(6):518-24. Epub 2010 Mar 11.
    View PubMed
  131. Naina HV, Patnaik MM, Ali UA, Chen D, Ashrani AA. Systemic fibrinolysis caused by tissue plasminogen activator-producing metastatic breast cancer. J Clin Oncol. 2010 Apr 10; 28(11):e167-8. Epub 2010 Jan 11.
    View PubMed
  132. Patnaik MM, Gangat N, Knudson RA, Keefe JG, Hanson CA, Pardanani A, Ketterling RP, Tefferi A. Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. Am J Hematol. 2010 Apr; 85(4):238-42.
    View PubMed
  133. Patnaik MM, Caramazza D, Gangat N, Hanson CA, Pardanani A, Tefferi A. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol. 2010 Feb 1; 84(2):105-8. Epub 2009 Nov 06.
    View PubMed
  134. Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ, Elliott MA, Litzow MR, Hanson CA, Pardanani A. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia. 2010 Jan; 24(1):105-9. Epub 2009 Oct 22.
    View PubMed
  135. Gangat N, Tefferi A, Thanarajasingam G, Patnaik M, Schwager S, Ketterling R, Wolanskyj AP. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. Eur J Haematol. 2009 Jul; 83(1):17-21. Epub 2009 Feb 19.
    View PubMed
  136. Patnaik MM, Tefferi A. Molecular diagnosis of myeloproliferative neoplasms. Expert Rev Mol Diagn. 2009 Jul; 9(5):481-92.
    View PubMed
  137. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, McClure RF, Li CY, Pardanani A. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009 Jun 4; 113(23):5727-36. Epub 2009 Apr 10.
    View PubMed
  138. Patnaik MM. Inclusion bodies in tick-borne diseases diagnosed in patients from northern Wisconsin. Clin Med Res. 2009 Jun; 7(1-2):45-7.
    View PubMed
  139. Patnaik MM, Tefferi A. The complete evaluation of erythrocytosis: congenital and acquired. Leukemia. 2009 May; 23(5):834-44. Epub 2009 Mar 19.
    View PubMed
  140. Nguyen T, Shepela C, Patnaik M, Jessurun J. Pulmonary nodules as an extra-intestinal manifestation of inflammatory bowel disease: a case series and review of the literature. Dig Dis Sci. 2009 May; 54(5):1135-40. Epub 2008 Aug 21.
    View PubMed
  141. Campagna AM, Patnaik MM. Advances in global biotechnology and local resources to treat malaria. Minn Med. 2009 Feb; 92(2):44-5.
    View PubMed
  142. Cunningham JM, Patnaik MM, Hammerschmidt DE, Vercellotti GM. Historical perspective and clinical implications of the Pelger-Huet cell. Am J Hematol. 2009 Feb; 84(2):116-9.
    View PubMed
  143. Patnaik MM, Rajasingham R, Deshpande A, Parmar G, Stauffer W. The Nepalese shepherd. J Travel Med. 2009 Jan-Feb; 16(1):68-71.
    View PubMed
  144. Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia. 2008 Nov; 14(6):1229-39.
    View PubMed
  145. Patnaik MM, Hammerschmidt D, van Burik JA, Jessurun J, Smyth P. Lepromatous leprosy masquerading as acute sarcoidosis: a case report and literature review. Minn Med. 2008 Nov; 91(11):30-3.
    View PubMed
  146. Campagna AM, Patnaik MM, Walker PF. Neglected tropical disease: challenges, progress, and hope. Minn Med. 2008 Jul; 91(7):42-4.
    View PubMed
  147. Patnaik MM, Deshpande AK. Diagnosis--Addison's disease secondary to tuberculosis of the adrenal glands. Clin Med Res. 2008 May; 6(1):29.
    View PubMed
  148. Patnaik MM, Tefferi A, Pardanani A. Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders. Curr Cancer Drug Targets. 2007 Aug; 7(5):492-503.
    View PubMed
  149. Patnaik MM, Haddad T, Morton CT. Pregnancy and thrombophilia. Expert Rev Cardiovasc Ther. 2007 Jul; 5(4):753-65.
    View PubMed
  150. Patnaik MM, Rindos M, Kouides PA, Tefferi A, Pardanani A. Systemic mastocytosis: a concise clinical and laboratory review. Arch Pathol Lab Med. 2007 May; 131(5):784-91.
    View PubMed
  151. Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA, Camoriano JK, Butterfield JH, Dewald GW, Tefferi A. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res. 2006 Aug; 30: (8)965-70.
    View PubMed
  152. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006 Jun; 133(5):468-92.
    View PubMed